Brilacidin
Antimicrobial / Anti-InflammatoryAlso known as: PMX-30063
Defensin MimeticsResearch phase: Phase 2Regulatory: Not approved. In clinical development for multiple indications.
Mechanism
Brilacidin is a synthetic small molecule that mimics defensin antimicrobial peptides. It is being studied for skin infections, oral mucositis, and was investigated for COVID-19.
Technical detail
Brilacidin (PMX-30063) is a non-peptidic arylamide foldamer that mimics the amphipathic structure and membrane-disrupting activity of host defense peptides (defensins). It has demonstrated efficacy in Phase 2 trials for acute bacterial skin infections (ABSSSI) and oral mucositis. Also investigated for antiviral activity against SARS-CoV-2 in vitro.